President Biden Signs New Legislation to Identify and Mitigate Organizational Conflicts of Interest in Federal Acquisition
Client Alert | 1 min read | 01.03.23
On December 27, 2022, President Biden signed into law the Preventing Organizational Conflicts of Interest in Federal Acquisition Act (S.3905) to strengthen the current rules relating to identification and mitigation of organizational conflicts of interest (OCIs) in federal acquisition. The Act focuses on updating the current FAR provision, Subpart 9.5, to provide clear definitions, examples, and guidance on potential OCIs and to consider expanding the Subpart to cover certain commercial and foreign relationships.
As currently drafted, FAR Subpart 9.5 provides general rules governing OCIs. Case law at the Court of Federal Claims and the Government Accountability Office have further identified three types of OCIs, “biased ground rules,” “impaired objectivity,” and “unequal access to information.” Under the Act, the FAR Council is meant to provide specific definitions and examples of the three types of OCIs.
The Act also instructs the FAR Council to provide executive agencies with standard solicitation provisions and contract clauses to address OCIs. Executive agencies will be able to tailor the solicitation provisions and contract clauses as necessary to address concerns associated with conflicts of interest and any considerations unique to the executive agency.
The Act directs the FAR Council to update the FAR’s OCI provisions in the next 18 months. We are expecting the FAR Council to issue proposed regulations, and contractors should be prepared to review the proposed changes and modify practices if needed once the final rules are issued.
Contacts
Insights
Client Alert | 4 min read | 08.29.25
Gender-Affirming Care Targeted for Potential False Claims Act Enforcement
On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments.
Client Alert | 4 min read | 08.28.25
9th Circuit Marches Forward to the Future Finding Digital Assets Are Protected Under Trademark Law
Client Alert | 2 min read | 08.27.25
CPSC Maintains Momentum on eFiling Requirements for Consumer Products
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions